566 results on '"Blackford, Amanda L"'
Search Results
2. ASO Visual Abstract: Using a CA19-9 Tumor Marker Gene Test to Assess Outcome After Pancreatic Cancer Surgery
3. Factors associated with weight gain in pre- and post-menopausal women receiving adjuvant endocrine therapy for breast cancer
4. Factors associated with worsening sexual function during adjuvant endocrine therapy in a prospective clinic-based cohort of women with early-stage breast cancer
5. The impact of weight loss on physical function and symptoms in overweight or obese breast cancer survivors: results from POWER-remote
6. Serum Carboxypeptidase Activity and Genotype-Stratified CA19-9 to Detect Early-Stage Pancreatic Cancer
7. In proportion: approaches for displaying patient-reported outcome research study results as percentages responding to treatment
8. Association of treatment-emergent symptoms identified by patient-reported outcomes with adjuvant endocrine therapy discontinuation
9. Housing assistance among patients with cancer: SEER-Medicare US Department of Housing and Urban Development data linkage.
10. Pancreatic Cancer Surveillance and Survival of High-Risk Individuals.
11. Geographic Disparities in Head and Neck Cancer Mortality and Place of Death.
12. A risk prediction tool for individuals with a family history of breast, ovarian, or pancreatic cancer: BRCAPANCPRO
13. A randomized, phase II trial of adjuvant immunotherapy with durable TKI-free survival in patients with chronic phase CML
14. Phase 1 study of the histone deacetylase inhibitor entinostat plus clofarabine for poor-risk Philadelphia chromosome-negative (newly diagnosed older adults or adults with relapsed refractory disease) acute lymphoblastic leukemia or biphenotypic leukemia
15. Incorporation of emergent symptoms and genetic covariates improves prediction of aromatase inhibitor therapy discontinuation
16. A Randomized Trial of Long-Term Oxygen for COPD with Moderate Desaturation
17. Using Tumor Marker Gene Variants to Improve the Diagnostic Accuracy of DUPAN-2 and Carbohydrate Antigen 19-9 for Pancreatic Cancer.
18. Development of Fibro-PeN, a clinical prediction model for moderate-to-severe fibrosis in children with nonalcoholic fatty liver disease.
19. Nationwide analysis of legal barriers impacting patients with cancer and caregivers.
20. Supplementary Data Tables S1-S5 from Diagnostic Performance of a Tumor Marker Gene Test to Personalize Serum CA19–9 Reference Ranges
21. Supplementary Data 2 from Diagnostic Performance of a Tumor Marker Gene Test to Personalize Serum CA19–9 Reference Ranges
22. Data from Diagnostic Performance of a Tumor Marker Gene Test to Personalize Serum CA19–9 Reference Ranges
23. Supplementary Data 1 from Diagnostic Performance of a Tumor Marker Gene Test to Personalize Serum CA19–9 Reference Ranges
24. A randomized intervention involving family to improve communication in breast cancer care
25. Severe Cytokine Release Syndrome after Haploidentical Peripheral Blood Stem Cell Transplantation
26. The effect of 1-day multidisciplinary clinic on breast cancer treatment
27. Immunomodulation with pomalidomide at early lymphocyte recovery after induction chemotherapy in newly diagnosed AML and high-risk MDS
28. Breast cancer survivorship care plans: what are they covering and how well do they align with national guidelines?
29. Risk of Marrow Neoplasms After Adjuvant Breast Cancer Therapy: The National Comprehensive Cancer Network Experience
30. Diagnostic Performance of a Tumor Marker Gene Test to Personalize Serum CA19–9 Reference Ranges
31. Prospective evaluation of finger two-point discrimination and carpal tunnel syndrome among women with breast cancer receiving adjuvant aromatase inhibitor therapy
32. Major Histocompatibility Mismatch and Donor Choice for Second Allogeneic Bone Marrow Transplantation
33. Randomized phase II trial of cytosine arabinoside with and without the CHK1 inhibitor MK-8776 in relapsed and refractory acute myeloid leukemia
34. Local Social Vulnerability as a Predictor for Cancer-Related Mortality Among US Counties
35. T cell immune deficiency rather than chromosome instability predisposes patients with short telomere syndromes to squamous cancers
36. Underutilization of Treatment for Regional Gastric Cancer Among the Elderly in the USA
37. Data from The Effects of a Remote-based Weight Loss Program on Adipocytokines, Metabolic Markers, and Telomere Length in Breast Cancer Survivors: the POWER-Remote Trial
38. Supplementary Tables 8 - 15 from Genetically Defined Subsets of Human Pancreatic Cancer Show Unique In Vitro Chemosensitivity
39. Supplementary Figures 1 - 5 from Genetically Defined Subsets of Human Pancreatic Cancer Show Unique In Vitro Chemosensitivity
40. Supplemental Figure 2 from The Effects of a Remote-based Weight Loss Program on Adipocytokines, Metabolic Markers, and Telomere Length in Breast Cancer Survivors: the POWER-Remote Trial
41. Supplementary table 8 from Smoking Modifies Pancreatic Cancer Risk Loci on 2q21.3
42. Supplementary Tables 16 - 22 from Genetically Defined Subsets of Human Pancreatic Cancer Show Unique In Vitro Chemosensitivity
43. Supplementary Materials from Estimating TP53 Mutation Carrier Probability in Families with Li–Fraumeni Syndrome Using LFSPRO
44. Supplemental Legend from The Effects of a Remote-based Weight Loss Program on Adipocytokines, Metabolic Markers, and Telomere Length in Breast Cancer Survivors: the POWER-Remote Trial
45. Data from Smoking Modifies Pancreatic Cancer Risk Loci on 2q21.3
46. Supplemental Table 1 from The Effects of a Remote-based Weight Loss Program on Adipocytokines, Metabolic Markers, and Telomere Length in Breast Cancer Survivors: the POWER-Remote Trial
47. Supplemental Data from A Phase 1 Study of the PARP Inhibitor Veliparib in Combination with Temozolomide in Acute Myeloid Leukemia
48. Supplementary Data from Smoking Modifies Pancreatic Cancer Risk Loci on 2q21.3
49. Supplemental Figure 1 from The Effects of a Remote-based Weight Loss Program on Adipocytokines, Metabolic Markers, and Telomere Length in Breast Cancer Survivors: the POWER-Remote Trial
50. Supplementary Tables 1 - 7 from Genetically Defined Subsets of Human Pancreatic Cancer Show Unique In Vitro Chemosensitivity
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.